Citations

Clear

3 citation(s) found for "Silver, Paul".

Relationships among intragastric meal distribution during gastric emptying scintigraphy, water consumption during water load satiety testing, and symptoms of gastroparesis
Parkman, Henry P. , Wilson, Laura , Silver, Paul G., Maurer, Alan H. , Sarosiek, Irene , Bulat, Robert, Kuo, Braden , Grover, Madhusudan , Farrugia, Gianrico , Shulman, Robert J. , Malik, Zubair , Miriel, Laura , Tonascia, James , Hamilton, Frank A., Pasricha, Pankaj J. , McCallum, Richard W. , Koch, Kenneth L. , Malik, Zubair , Parkman, H P , Kuo, Braden , Silver, Paul, Chumpitazi, Bruno P. , Abell, Thomas L.

Mayo Clinic

American Journal of Physiology-Gastrointestinal and Liver Physiology | August 8, 2023 | Volume: 325 | Issue: 5 | Pages: G407-G417

10.1152/ajpgi.00065.2023 | PMID 37552206 Get It

IMD0 and WLST were assessed for their clinical utility in assessing patients with symptoms of gastroparesis. Low IMD0 is associated with less gastric retention and less heartburn. Volume of water consumed during WLST, while associated with IMD0, has associations with early satiety, postprandial fullness, loss of appetite, and nausea. IMD0 and WLST appear to overlap somewhat in their assessment of gastric physiology in adults with symptoms of gastroparesis but relate to different dyspeptic symptoms.
Thermal ablation compared to stereotactic body radiation therapy for hepatocellular carcinoma: A multicenter retrospective comparative study
Kim, Hannah P. , Singal, Amit G. , Owen, Dawn , Parikh, Neehar D. , Rose, Steven C., McGinty, Katrina , Agala, Chris B. , Burke, Lauren M. , Abate, Anjelica, Do, John, Folkert, Michael R. , Forbes, C.D., Hattangadi‐Gluth, Jona A. , Hayashi, Paul H. , Jones, Keri, Lawrence, Theodore S. , Maurino, C. , Mayo, Charles S. , Pak, Taemee , Patil, Preethi, Simpson, Daniel R. , Tepper, Joel E. , Thapa, Diwash , Moon, Andrew M , Singal, Amit , Owen, Dawn , Parikh, Neehar D , McGinty, Katrina A , Burke, Lauren M , Altun, Ersan , Folkert, Michael R , Hayashi, Paul H , Khatri, Gaurav , Kono, Yuko , Lawrence, Theodore S , Tepper, Joel E , Gerber, David A , Mendiratta-Lala, Mishal , Beyer, Christian, Forbes, Chalon, Khatri, Gaurav , Mauro, David M. , Sanders, Emily C. , Yanagihara, Ted K. , Wang, Kyle , Gerber, David A.

Mayo Clinic

Hepatology Communications | June 14, 2023 | Volume: 7 | Issue: 7 | Pages: No page available

10.1097/hc9.0000000000000184 | PMID 37314737 Get It

Background & Aims: Early-stage HCC can be treated with thermal ablation or stereotactic body radiation therapy (SBRT). We retrospectively compared local progression, mortality, and toxicity among patients with HCC treated with ablation or SBRT in a multicenter, US cohort. Approach & Results: We included adult patients with treatment-naïve HCC lesions without vascular invasion treated with thermal ablation or SBRT per individual physician or institutional preference from January 2012 to December 2018. Outcomes included local progression after a 3-month landmark period assessed at the lesion level and overall survival at the patient level. Inverse probability of treatment weighting was used to account for imbalances in treatment groups. The Cox proportional hazard modeling was used to compare progression and overall survival, and logistic regression was used for toxicity. There were 642 patients with 786 lesions (median size: 2.1 cm) treated with ablation or SBRT. In adjusted analyses, SBRT was associated with a reduced risk of local progression compared to ablation (aHR 0.30, 95% CI: 0.15–0.60). However, SBRT-treated patients had an increased risk of liver dysfunction at 3 months (absolute difference 5.5%, aOR 2.31, 95% CI: 1.13–4.73) and death (aHR 2.04, 95% CI: 1.44–2.88, p < 0.0001). Conclusions: In this multicenter study of patients with HCC, SBRT was associated with a lower risk of local progression compared to thermal ablation but higher all-cause mortality. Survival differences may be attributable to residual confounding, patient selection, or downstream treatments. These retrospective real-world data help guide treatment decisions while demonstrating the need for a prospective clinical trial.
Buspirone for early satiety and symptoms of gastroparesis: A multi‐centre, randomised, placebo‐controlled, double‐masked trial ( BESST )
Parkman, Henry P. , Yates, Katherine P. , Sarosiek, Irene , Bulat, Robert, Koch, Kenneth L. , Grover, Madhusudan , Farrugia, Gianrico , Silver, Paul J., Abdullah, Amirah, Maurer, Alan H. , Malik, Zubair , Miriel, Laura , Tonascia, James , Hamilton, Frank A., Pasricha, Pankaj J. , McCallum, Richard W. , Grover, Madhusudan , Farrugia, Gianrico , Parkman, H P , Abell, Thomas L. , Kuo, Braden , Silver, Paul

Mayo Clinic

Alimentary Pharmacology & Therapeutics | April 13, 2023 | Volume: 57 | Issue: 11 | Pages: 1272-1289

10.1111/apt.17479 | PMID 37052334 Get It

Summary Background Patients with gastroparesis and related disorders have symptoms including early satiety, postprandial fullness and bloating. Buspirone, a 5‐HT 1 receptor agonist, may improve fundic accommodation. Aim To determine if buspirone treatment improves early satiety and postprandial fullness in patients with symptoms of gastroparesis. Methods This 4‐week multi‐centre clinical trial randomised patients with symptoms of gastroparesis and moderate‐to‐severe symptoms of fullness (Gastroparesis Cardinal Symptom Index [GCSI] early satiety/postprandial fullness subscore [ES/PPF]) to buspirone (10 mg orally) or placebo three times per day. The primary outcome was a change in the ES/PPF from baseline to 4 weeks. The primary analysis was per protocol intention‐to‐treat ANCOVA of between‐group baseline vs. 4‐week differences (DoD) in ES/PPF adjusted for baseline ES/PPF. Results are reported using both nominal and Bonferroni (BF) p values. Results and conclusions Ninety‐six patients (47 buspirone, 49 placeboes; 92% female, 50% delayed gastric emptying, 39% diabetic) were enrolled. There was no between‐groups difference in the 4‐week ES/PPF primary outcome: −1.16 ± 1.25 (SD) on buspirone vs −1.03 ± 1.29 (SD) on placebo (mean DoD: −0.11 [95% CI: −0.68, 0.45]; p = 0.69). Buspirone performed better than placebo in patients with severe‐to‐very severe bloating at baseline compared to patients with none to moderate: (ES/PPF DoD = −0.65 vs. 1.58, p TX*GROUP = 0.003; p BF = 0.07). Among individual GCSI symptoms, only bloating appeared to improve with buspirone vs. placebo. Conclusions Patients with moderate‐to‐severe early satiety/postprandial fullness and other symptoms of gastroparesis did not benefit from buspirone treatment to improve the ES/PPF primary outcome compared with placebo. There was a suggestion of the benefit of buspirone in patients with more severe bloating. Trial Registration: ClinicalTrials.gov NCT0358714285.